FDA flags rare eye-stroke risk across GLP-1 drugs as Indian use surges
The FDA has ordered GLP-1 drug labels to flag a potential risk of NAION. The move sharpens scrutiny as cheaper weight-loss medicines reach more Indian patients.
Attributed summary
The FDA has ordered GLP-1 drug labels to flag a potential risk of NAION. The move sharpens scrutiny as cheaper weight-loss medicines reach more Indian patients.
Read the original report — India Today
Storywire publishes attributed summaries for discoverability. Full reporting remains with the original publisher — we do not republish restricted full text.
